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Objective. The incidence of peripheral vascular disease (PVD) and angiography/angioplasty is rising annually. The UK
Small Aneurysm Trial and other trials have shown renal function is a predictor of increased mortality and failed infrain-
guinal bypass despite patent vessels. Renal function is classically assessed by serum creatinine (SCr). However, SCr can be
normal despite significant renal impairment. A more sensitive test is creatinine clearance (CrCl) as determined by 24-hour
urine collection in combination with SCr. We studied the incidence of renal impairment, as defined by CrCl, in PVD
patients with normal SCr.
Methodology. All patients with PVD sufficient to necessitate angiography and normal SCr (120 mmol/l e men;
97 mmol/l e women) had their CrCl assessed prior to angiography: using both 24-hour urine collection and the Cock-
croft-Gault formula. Various blood tests, a detailed history and examination were performed. A control group of arthritic
patients, age and sex-matched with similar SCr, also had their CrCl determined.
Results. 65 of 76 patients (86%) with normal SCr had a subnormal CrCl (<100 ml/min) and 49 (65%) had a CrCl below
60 ml/min. In the control group of arthritic patients, the proportion having impaired CrCl was significantly less e 67%
below 100 mls/min (p¼ 0.0471) and only 15% below 60 mls/min (p< 0.0001). The median and interquartile range CrCl
of 52 [38e81] mls/min for PVD patients was significantly worse than for control patients (80 [68e119] mls/min e
p< 0.0001). The Cockcroft-Gault formula for calculating CrCl did not correlate well with the urinary CrCl for the control
group but did for PVD patients (p< 0.0001). Factors associated with a significantly reduced CrCl were age of at least 75
years, SCr of at least 85 mmol/l and a history of coronary heart disease (all p< 0.05). This had a sensitivity of 88% and
specificity of 82% for identifying subnormal CrCl. Statin use was associated with a significantly improved CrCl
(p¼ 0.040).
Conclusion. Most PVD patients with normal serum creatinine have occult, significantly impaired renal function as
defined by creatinine clearance. Vascular surgeons should include creatinine clearance in pre-operative assessment of renal
function especially in patients over 75 years old, with a history of coronary heart disease or a serum creatinine over
85 mmol/l. The method of determining creatinine clearance could be the Cockcroft-Gault calculation or ideally 24-hour uri-
nary creatinine clearance measurement. This would allow appropriate early referral to a nephrologist for further investi-
gation and management. It is worth noting that statin use seems to be associated with a protective effect on renal function.
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Renal dysfunction is an important risk factor in the
outcome of many surgical procedures.1e3 It has been
shown that poor renal function is associated with
increased mortality in aneurysm surgery4 especially
endovascular repair5 and failed infrainguinal bypass
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dialysis-dependent patients,6e12 although these obser-
vations are not universal.13,14 The incidence of periph-
eral vascular disease (PVD) and angiography/
angioplasty is rising annually.
Renal function is classically assessed by serum cre-
atinine (SCr). Glomerular filtration rate (GFR) is the
true reflection of renal function and should be around
125 mls/min in the typical adult. However, SCr does
not usually rise until GFR has fallen by 50% or
more.15 Furthermore, SCr depends on lean body
weight (LBW), age and sex and is therefore inaccurate
in a third of patients aged between 40e49 and 90% inrved.
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developed to correct for the inaccuracies posed by
weight, age and sex: Cockcroft-Gault, Modification
of Diet in Renal Disease and the Bjorssen equation,
but the latter two are laborious and impractical.17
Direct measurements of GFR include isotope, inulin
and creatinine clearance.18 Of these the most practical
for screening purposes is creatinine clearance (CrCl)
because it does not require the addition of any marker
and is simply determined from a 24-hour urine collec-
tion in combination with SCr.
We therefore studied the incidence of renal impair-
ment in PVD patients with normal SCr, as defined by
both the Cockcroft-Gault equation and urinary CrCl. A
control group of patients, age and sex-matched were
selected from arthritic patients awaiting joint replace-
ment surgery for comparison purposes.
Methods and Materials
We invited all patients with peripheral vascular
disease (PVD) and normal serum creatinine (SCr)
going for elective angiography or angioplasty to par-
ticipate in this study. In our hospital this normal SCr
is up to 120 mmol/l for men or 97 mmol/l for women.
Approval was obtained from the Ethics Committee
of the Royal Free Hampstead NHS Trust. Calculated
Creatinine clearance was done using the following
Cockcroft-Gault formula:
CrClðml=minÞ ¼ ð140 age½yearsÞ LBW½kg
SC½mmol=l  0:81
 0:85½women
LBW½kg ¼ 2:3 ðHeight½inches  60Þ þ 50
 4:5½women
All patients had a relevant history and examination
performed with some specific investigations per-
formed prior to angiography. In particular, creatinine
clearance (CrCl) was measured after admission in the
ward under the supervision of experienced nurses.
Creatinine clearance was done by 24-hour urine
collection.
A group of arthritic patients scheduled for hip or
knee replacement surgery, but who did not have
PVD were selected as controls. These patients were
selected to match the age and sex profile of PVD
patients and again had their CrCl measured together
with other relevant history, examination and
investigations.Statistics
With regard to 24-hour urinary creatinine clearance
(CrCl), this is a standard test performed routinely in
our Biochemistry Department which is fully and reg-
ularly validated. In keeping with other laboratories,
the coefficient of variation from repeated 24 h urine
collections is between 11e30%. Given almost all meas-
urements were done whilst the patients were in hospi-
tal and supervised by experienced nurses, we feel
confident that our results are around 11%.
Analysis comparing risk factors between two
groups using continuous variables (e.g. - age) was
with two-tailed T-tests except where the risk factor
used segregation into groups (e.g. - presence or ab-
sence of diabetes) - here Fisher’s exact test was used.
Correlation between continuous variables was done
using Pearson’s correlation coefficient with two-tailed
significance.
For the analysis of risk factors predicting renal dys-
function (as defined by impaired creatinine clear-
ance), a general linear model was applied (SPSS
software). Variables which demonstrated significant
associations with creatinine clearance in univariate
analysis were included in the general linear model.
Results are given as median with interquartile
range (IQR).
Results
76 PVD patients with normal SCr were recruited to this
study e 50 male and 26 female. All patients had their
Table 1.
Criteria PVD Controls p
SCr: mmol/l 88 [74e100] 81 [73e96] 0.2863
Age: years 75 [64e85] 65 [62e75] 0.0543
Gender (M:F) 50:26 18:9 1.000
Key: SCr: serum creatinine; M: Male; F: Female; PVD: peripheral
vascular disease; controls: arthritic patients. Values are creatinine
clearances: median [interquartile range]. P-values from two-tail
T-test except Fisher’s exact test used for gender.
Table 2A.
Criteria PVD Controls p
Urinary CrCl: mls/min 52 [38e81] 80 [68e119] <0.0001
Urinary CrCl - <100:100 65:11 18:9 0.0471
Urinary CrCl - <60:60 49:27 4:23 <0.0001
Calculated CrCl: mls/min 55 [42e73] 63 [50e79] 0.2725
Calculated CrCl - <100:100 68:7 27:0 0.1850
Calculated CrCl - <60:60 44:31 10:27 0.0722
Key: CrCl: creatinine clearances; PVD: peripheral vascular disease;
controls: arthritic patients. Values are median [interquartile range].
P-values from Fisher’s exact test except for continuous variables
(measured in mls/min) which use the two-tail T-test.Eur J Vasc Endovasc Surg Vol 32, September 2006
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but one had their creatinine clearance calculated using
the Cockcroft-Gault method: the missing patient
was an amputee whose height could not be measured.
The 27 control patients who had arthritis but not
PVD were matched for serum creatinine, gender and
age (Table 1).
The CrCl median and IQR for PVD patients was
52 [38e81] mls/min. 65 patients (86%) with PVD
had subnormal renal function as defined by 24-hour
urinary CrCl (<100 mls/min), with 49 (64%) having
CrCl< 60 mls/min representing significant renal im-
pairment e less than half normal GFR. In comparison
the control patients had a significantly higher median
and IQR CrCl of 80 [68e119] mls/min (p< 0.0001).
Only 18 of 27 (67%) of the controls had subnormal
CrCl (p¼ 0.0471), with only 4 (15%) having significant
renal impairment with a CrCl< 60 mls/min
(p< 0.0001). As can be seen from Table 2A this sug-
gests that PVD patients have statistically significant
reduction in renal function compared to age and
sex-matched controls. Importantly, these differences
cannot be detected by alternative measures of renal
function like SCr (p¼ 0.2863) and calculated CrCl
(p¼ 0.2725) using the Cockcroft-Gault measurement
(Tables 1 & 2A). Indeed Cockcroft-Gault is reliable
when correlated with urinary CrCl for PVD patients
but not the control arthritic patients (Table 2B).
Univariate analysis shows that only a history of cor-
onary heart disease (CHD) and no history of smoking
were associated with decreased CrCl, whereas previ-
ous cerebrovascular disease (CVD), hypertension,
Table 2B.
Patient Group Pearson Correlation Coefficient p
PVD 0.5918 <0.0001
Control 0.1356 0.4748
Key: PVD: peripheral vascular disease; controls: arthritic patients.
P-values from Pearson Correlation coefficient.
Table 3.
Risk Factor Present Absent p
CHD 44 [36e57] 57 [37e95] 0.0073
CVD 47 [37e68] 52 [38e84] 0.3064
DM 50 [37e72] 52 [38e82] 0.3449
HT 54 [43e82] 42 [29e62] 0.2367
[ Cholesterol 56 [42e85] 45 [28e64] 0.0954
Overweight (BMI > 25) 56 [43e81] 48 [33e81] 0.8345
Ever smoked 54 [39e84] 41 [27e52] 0.0159
Male gender 53 [39e86] 46 [28e67] 0.1360
Key: CHD: coronary heart disease; CVD: cerebrovascular disease;
DM: diabetes mellitus; HT: hypertension; [ Cholesterol: hyper-
cholesterolaemia; BMI: body mass index. Values are creatinine clear-
ances: median [interquartile range]. P-values from two-tail T-test.Eur J Vasc Endovasc Surg Vol 32, September 2006diabetes, hypercholesterolaemia, gender and being
overweight made no difference. (Table 3).
Of the various drugs that patients were taking only
statins (Table 4) were associated with a significantly
improved CrCl from 46 [30e61] to 56 [45e91]
(p¼ 0.0308).
Increasing serum creatinine, urea and age were sig-
nificantly associated with decreased CrCl (Table 5A)
with the key cut-off values being SCr of 85 mmol/l,
Urea of 6.6 mmols/l and age of 75 years (Table 5B
and Figs. 1 and 2).
The factors entered into the general linear model on
the basis of univariate analysis were serum creatinine,
age, statin use, history of coronary heart disease
and smoking. It was decided not to include serum urea
in the general linear model as it was simply another
measure of renal function that was highly significantly
correlatedwithserumcreatinine (p< 0.0001eTable5A).
The results of the general linear model (Table 6)
showed that statin therapy was significantly associ-
ated with improved CrCl (p¼ 0.040), whereas rising
SCr (p¼ 0.005) and history of CHD (p¼ 0.024) were
significantly associated with impaired CrCl. Smoking
and age as a continuous variable did not show any
significant association with CrCl. However, age of
75 years and above was significantly associated with
impaired CrCl (p¼ 0.023), as was SCr of 85 mmol/l
and above (p¼ 0.003).
Overall, renal dysfunction (CrCl< 100 mls/min) is
more likely to be found in patients with any of the fol-
lowing risk factors: age 75 years and above, serum
creatinine of at least 85 mmol/l or history of coronary
heart disease. Having any of these risk factors had
a sensitivity of 88%, specificity of 82%, positive pre-
dictive value of 97% and a negative predictive value
Table 4.
Drug Not Taking Drug Taking Drug p
Anti-hypertensives 44 [29e63] 52 [38e82] 0.4721
Anti-platelets 53 [29e83] 47 [36e56] 0.0554
Anti-diabetic 52 [39e82] 46 [32e59] 0.1130
Statins 46 [30e61] 56 [45e91] 0.0308
Key: Values are creatinine clearances: median [interquartile range].
P-values from two-tail T-test.
Table 5A.
Factor A Factor B Pearson Correlation Coefficient p
CrCl Age 0.3962 0.0004
CrCl SCr 0.3445 0.0023
CrCl Urea 0.3869 0.0006
SCr Urea 0.4565 <0.0001
Key: CrCl: Creatinine Clearance; SCr: serum creatinine. P-values
from Pearson Correlation coefficient.
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use of statins as a fourth risk factor for renal dysfunc-
tion has a sensitivity of 98%, specificity of 55%, posi-
tive predictive value of 93% and a negative
predictive value of 86% (Tables 7A & 7B).
Discussion
This study found that the normal screening tool for
assessing renal function, serum creatinine, can be
within the normal range even though the vast major-
ity of PVD patients (86%) will have renal impairment
(GFR< 100 mls/min) as measured by 24-hour urinary
creatinine clearance (UrCrCl).
It is well recognized that calculating GFR using the
Cockcroft-Gault method for creatinine clearance
(C-GCrCl) tends to underestimate renal function in
the elderly, especially over 70 year olds,16,17 which is
the age profile of most PVD patients. This is reflected
in the age-matched control group where the C-GCrCl
(63 [50e79] mls/min) was significantly lower (p¼
0.0004) than the actual UrCrCl (80 [68e119]
mls/min), and the C-GCrCl showed all controls had
subnormal renal function whereas 9 out of 27 had
a UrCrCl within the normal range. However, the
SCr vs CrCl


















Fig. 1. Key: CrCl: Creatinine Clearance; SCr: serum creati-
nine. P-value from two-tail T-test.
Table 5B.
Cut-off Value Less than Equal to/greater than p
SCr of 85 mmol/l 71 [43e103] 44 [34e58] 0.0002
Urea of 6.6 mmols/l 58 [46e102] 41 [31e56] 0.0006
Age of 75 years 76 [45e99] 41 [29e54] <0.0001
Key: SCr: serum creatinine. Values are creatinine clearances: median
[interquartile range]. P-values from two-tail T-test.very poor renal function of PVD patients means that
C-GCrCl does predict that the vast majority of PVD
patients (91%) have subnormal renal function
(GFR< 100 mls/min) and the mean GFR is similar
(p ¼ 0.8347) for both UrCrCl (52 [38e81] mls/min)
and C-GCrCl (55 [42e73] mls/min).
Theoretically patients with very significant renal
impairment e 50% or more decline in normal GFR
represented by a value under 60 mls/min19 - should
be picked up by serum creatinine (SCr). However,
our study found that 65% of PVD patients with nor-
mal SCr had UrCrCl< 60 mls/min. Using C-GCrCl
59% were predicted to have this - again an impressive
result. However, 25% of patients with UrCrCl of
under 60 mls/min were missed by the C-GCrCl
calculation.
The question then is how important is accurate es-
timation of renal function. As previously mentioned
renal function is an important predictor of surgical
outcome. However, perhaps more importantly is the
fact that renal dysfunction is a critical risk factor in
Table 6.
Risk Factor Present Absent p
SCr Continuous Variable 0.005
Age Continuous Variable 0.106
CHD 44 [36e57] 57 [37e95] 0.024
Statins 56 [45e91] 46 [30e61] 0.040
Ever smoked 54 [39e84] 41 [27e52] 0.078
SCr under 85 mmol/l 71 [43e103] 44 [34e58] 0.003
Age under 75 years 76 [45e99] 41 [29e54] 0.023
Key: SCr: serum creatinine; CHD: coronary heart disease. Values are
creatinine clearances: median [interquartile range]. P-values from
general linear model.
Age vs CrCl


















Fig. 2. Key: CrCl: Creatinine Clearance. P-value from two-
tail T-test.Eur J Vasc Endovasc Surg Vol 32, September 2006
298 S. T. Rashid et al.the development of acute renal failure (ARF).20 ARF
occurs in between 2e7% of hospital patients21e23
with a mortality if uncomplicated of between 5e10%
rising to over 50% if another organ system has failed:
an outcome that has not improved over several
decades.24
Given that measuring renal function is important
the next question is how best to measure it. The
‘‘gold standard’’ for determining GFR is by measuring
the clearance of exogenous substances such as iohexol,
inulin, 51Cr-EDTA, 99mTc-labelled diethylenetriamine
pentaacetic acid (DTPA), or 125I-labeled iothalamate.
Unfortunately, these techniques are time-consuming,
labor-intensive and expensive.25
For the last few decades, serum or plasma creati-
nine (SCr) has become the most commonly used se-
rum marker of renal function. SCr is a metabolic
product of muscle tissue which circulates in the blood
unbound and is freely filtered by the glomerulus, but
also secreted in small amounts in the proximal tu-
bules. Intraindividual variability is low though SCr
blood concentrations are affected by age and gender,
with interindividual variation. As plasma concentra-
tions increase, tubular secretion of SCr increases, lead-
ing to an overestimation of GFR in patients with
moderate to severe decreases in GFR.25e29
Measurement of creatinine clearance (CrCl) by de-
termining its concentration in timed urine collections
and simultaneously in blood correlates with gold
standard exogenous methods better than SCr.26 How-
ever, this can be cumbersome and prone to error in the
outpatient setting. Fortunately all our patients had
Table 7A.
Key: RF: Risk Factor; CHD: coronary heart disease; SCr: serum cre-
atinine; CrCl: Creatinine Clearance; Impaired: CrCl< 100 ml/min.
Values are number of patients in each group.
Table 7B.
Key: RF: Risk Factor; CHD: coronary heart disease; SCr: serum cre-
atinine; Impaired¼Creatinine Clearance< 100 ml/min. Values are
% with 95% confidence intervals in brackets.Eur J Vasc Endovasc Surg Vol 32, September 2006UrCrCl measured under the supervision of experi-
enced nurses whilst inpatients.
Cystatin C offers a potentially superior option to
creatinine. However, a recent review found 15 studies
showing cystatin C to be superior but 9 were equi-
vocal.25 Furthermore, there is intraindividual vari-
ability30 and the immunoassay measurement method
makes this test prohibitively expensive.
The conclusion that can thus be drawn is that se-
rum creatinine is unreliable as an assessment of renal
function in patients with peripheral vascular disease.
The Cockcroft-Gault formula is a reasonably good
estimation of renal function in PVD patients, though
creatinine clearance determined by 24-hour urine
collection is a relatively simple and cheap method to
determine renal function more accurately.
This methodology may still be prohibitive to some
and therefore we attempted to determine which
patients are most at risk of renal dysfunction and who
would thus benefit from this extra investigation. We
suggest patients 75 years and above, a serum creatinine
above 85 mmol/l or a history of coronary heart disease
identifies those at most risk of renal impairment with
a sensitivity of 88% and specificity of 82%. Adding
non-statin use to the above three risk factors for renal
impairment raises sensitivity to 98%but specificity falls
to 55%. It would therefore appear that those patients
with PVD who do not yet take statins may be missing
out on a potentially renoprotective drug, which agrees
with a previous study in our department.31
Patients discovered to have renal dysfunction and
undergoing angiography could have their manage-
ment altered by specifically looking for renal artery
stenosis, the use of renoprotection with hydration,32,33
agents like sodium bicarbonate34 and perhaps
N-Acetylcysteine,35e38 or the preferential use of alter-
native contrast media like iso-osmolar contrast39 or
gadolinium.40 Further work is now needed on the rel-
ative contributions of intrarenal disease, renal artery
stenosis and atheroembolism to the decline in renal
function in PVD patients.
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